title: A(2b) adenosine receptors can change their spots.
abstract: Recently, a central role for the A(2b) adenosine receptor in a variety of cardiovascular functions including inflammation, erectile function, coronary artery dilation, asthma and cardioprotection has been demonstrated. Despite this evidence, the low-affinity A(2b) adenosine receptor is still poorly understood. This receptor appears to be very promiscuous in its coupling. In most tissues, it couples to G(s) much like its cousin, the A(2a) adenosine receptor, but in mast cells and now, most recently, in cardiac fibroblasts, the A(2b) receptor also couples to G(q). Because of its low affinity, this receptor was originally thought unlikely to play any important physiological role. But the sensitivity of A(2b) adenosine receptors can be greatly increased by interaction with protein kinase C (PKC) making this receptor, under various conditions, both an activator and a target of PKC. We have recently documented a third coupling involving G(i). This plasticity and versatility of A(2b) adenosine receptors position them as potential triggers of signalling in multiple signalling cascades in many physiological responses, making this a most interesting receptor indeed.
authors.affiliation: Department of Physiology, University of South Alabama, Mobile, 36688, USA. mcohen@usouthal.edu
authors.forename: Michael V
authors.initials: MV
authors.lastname: Cohen
authors.forename: Xiulan
authors.initials: X
authors.lastname: Yang
authors.forename: James M
authors.initials: JM
authors.lastname: Downey
mesh_terms: D000818:Animals; D043802:GTP-Binding Protein alpha Subunits, Gq-G11 / Q000378:metabolism; D006801:Humans; D011485:Protein Binding; D011493:Protein Kinase C / Q000378:metabolism; D043704:Receptor, Adenosine A2B / Q000378:metabolism / Q000502:physiology*
chemical_list: D043704:Receptor, Adenosine A2B; D011493:Protein Kinase C; D043802:GTP-Binding Protein alpha Subunits, Gq-G11
references.citation: Br J Pharmacol. 2010 Apr;159(8):1598-607
references.pmid: 20050850
references.citation: J Physiol Pharmacol. 2005 Dec;56(4):587-97
references.pmid: 16391416
references.citation: Cardiovasc Res. 2006 May 1;70(2):308-14
references.pmid: 16545350
references.citation: Cardiovasc Res. 2001 Oct;52(1):25-39
references.pmid: 11557231
references.citation: Circ Res. 1995 Feb;76(2):242-51
references.pmid: 7834835
references.citation: J Mol Cell Cardiol. 2007 Sep;43(3):262-71
references.pmid: 17632123
references.citation: Am J Physiol. 1996 May;270(5 Pt 2):H1655-61
references.pmid: 8928871
references.citation: Mol Pharmacol. 1999 Oct;56(4):705-13
references.pmid: 10496952
references.citation: Pharmacol Rev. 1997 Dec;49(4):381-402
references.pmid: 9443164
references.citation: Cell Signal. 2003 Sep;15(9):813-27
references.pmid: 12834807
references.citation: Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H441-9
references.pmid: 16155103
references.citation: Am J Physiol Heart Circ Physiol. 2002 Feb;282(2):H437-44
references.pmid: 11788390
references.citation: Circulation. 1991 Jul;84(1):350-6
references.pmid: 2060105
references.citation: Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92
references.pmid: 17874974
references.citation: J Clin Invest. 2006 Jul;116(7):1913-23
references.pmid: 16823489